NCT04287920View on ClinicalTrials.gov

Acamprosate Safe to Use in Individuals With Liver Disease.

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

January 5, 2022

Study Completion Date

January 5, 2022

Conditions
Alcohol-related Liver Disease
Interventions
DRUG

Acomprosate

Acamprosate will be administered orally and will be dosed at 333 mg three times a day, if tolerated it will be increased to 666 mg three times a day. Acamprosate will be administered for a total of 3 months

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04287920 - Acamprosate Safe to Use in Individuals With Liver Disease. | Biotech Hunter | Biotech Hunter